<code id='5BB815925D'></code><style id='5BB815925D'></style>
    • <acronym id='5BB815925D'></acronym>
      <center id='5BB815925D'><center id='5BB815925D'><tfoot id='5BB815925D'></tfoot></center><abbr id='5BB815925D'><dir id='5BB815925D'><tfoot id='5BB815925D'></tfoot><noframes id='5BB815925D'>

    • <optgroup id='5BB815925D'><strike id='5BB815925D'><sup id='5BB815925D'></sup></strike><code id='5BB815925D'></code></optgroup>
        1. <b id='5BB815925D'><label id='5BB815925D'><select id='5BB815925D'><dt id='5BB815925D'><span id='5BB815925D'></span></dt></select></label></b><u id='5BB815925D'></u>
          <i id='5BB815925D'><strike id='5BB815925D'><tt id='5BB815925D'><pre id='5BB815925D'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:fashion    Page View:6
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In